2026-05-25T12:53:41Z https://www.peertechzpublications.org/oai-pmh

oai:www.peertechzpublications.org:10.17352/aprc.000023 2017-05-24 PTZ.APRC:VOL3

Effectiveness of Asthma Inhaler Pharmacotherapy must take into consideration both the device and drug and which is guided by clinically meaningful outcomes Elissa M McDonaldFelix SF Ram<p><strong>Introduction: </strong>The&nbsp; inhalation&nbsp; route&nbsp; remains&nbsp; the&nbsp; mainstay&nbsp; of&nbsp; therapy&nbsp; for asthma&nbsp; and&nbsp; chronic obstructive&nbsp; pulmonary&nbsp; disease&nbsp; (COPD). This confers&nbsp; a&nbsp; number&nbsp; of&nbsp; advantages&nbsp; such&nbsp; as&nbsp; delivery&nbsp; of medication&nbsp; directly&nbsp; to&nbsp; the site of&nbsp; action&nbsp; resulting&nbsp; in&nbsp; faster onset. It also allows&nbsp; smaller&nbsp; doses&nbsp; to&nbsp; be&nbsp; administered&nbsp; and therefore significantly reduces systemic side effects compared with oral therapy. The drug treatment regime for the majority of patients&nbsp; with&nbsp; asthma&nbsp; and&nbsp; COPD is straightforward and is documented in many guidelines [1-3]. However, the choice of which inhaler device to use is less straightforward. Rather than being spoilt for choice, we are frequently confused by the ever-increasing&nbsp; number&nbsp; of&nbsp; devices&nbsp; available.&nbsp; Although&nbsp; inhalation therapy&nbsp; is&nbsp; now&nbsp; the&nbsp; mainstay&nbsp; of&nbsp; asthma&nbsp; treatment,&nbsp; for&nbsp; most patients&nbsp; such&nbsp; treatment&nbsp; is&nbsp; still&nbsp; not&nbsp; optimal.</p> Archives of Pulmonology and Respiratory Care - Peertechz Publications 2017-05-24 Review Article https://doi.org/10.17352/aprc.000023 en Copyright © Elissa M McDonald et al.